Q3 2024 PEMGARDA™ (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with $106.9 million in cash and cash equivalentsTargets ...

Invivyd Inc (IVVD) reports $9.3 million in revenue and outlines plans for profitability by mid-2025 despite facing commercial headwinds.

Regulating drug discovery and pharmaceutical manufacturing, the FDA ensures the safety and effectiveness of innovative ...

OraQuick® HCV Self-test receives initial orders following receipt of WHO pre-qualification status Expanding Sample Management applications into blood proteomics Exiting Risk Assessment testing ...

Invivyd reports clinical efficacy data from CANOPY phase 3 trial of pemivibart: Waltham, Massachusetts Friday, November 15, 2024, 18:00 Hrs [IST] Invivyd, Inc, a biopharmaceutical ...

The US FDA has revoked the Emergency Use Authorization (EUA) for Cue Health’s two Covid-19 tests and has classified the ...

As expected, the FDA has moved quickly to grant emergency use authorisation (EUA) to two new-generation COVID-19 mRNA vaccines from Pfizer/BioNTech and Moderna, both targeting the new Omicron ...

The Pfizer/BioNTech bivalent COVID-19 vaccine (Original and Omicron BA.4/BA.5) has the FDA’s EUA for use in individuals 5 years and over as a single booster dose administered at least two months ...

In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for its first mAb in a planned series of innovative antibody candidates. Visit  to learn more.

Preliminary Q3 2024 PEMGARDA (pemivibart) net product revenue of $9.3 million; Invivyd ended Q3 2024 with approximately $107 million in cash and cash equivalentsExpects to finish 2024 with $65 million ...

Cepheid today announced that The World Health Organization (WHO) has listed Xpert Mpox under its Emergency Use Listing (EUL) procedure. The EUL process assesses the quality, safety, and performance of ...

OraSure is an NCAV opportunity with stable operations demonstrated by consistent historical cash flow generation. Find out ...